Drug Discovery 2013
Print Print
Presentation
Tue 3 September
4 September
DAY 1Charter 1Charter 2Charter 3Charter 4Exchange 10
DAY 2
DAY 1Charter 1Charter 2Charter 3Charter 4Exchange 10
DAY 2
9:00 9:00:
9:05: 9:05:
9:10: 9:10:
9:15: Non-invasive biomarkers that predict treatment benefit from biologic therapies in asthma
09:15 (45 mins)
Joe Arron, Genentech  
 Building Tissue high throughput
09:15 (45 mins)
Clemens van Blitterswijk, Twente University  
 Through a Membrane, Darkly
09:15 (45 mins)
Dennis Smith, Liverpool University, University of Capetown  
 The inexorable rise of biologic drugs
09:15 (45 mins)
Kevin Johnson, Index Ventures  
 9:15:
9:20: 9:20:
9:25: 9:25:
9:30: 9:30:
9:35: 9:35:
9:40: 9:40:
9:45: 9:45:
9:50: 9:50:
9:55: 9:55:
10:00 Strategies for Target Validation
10:00 (30 mins)
Lorenz Mayr, AstraZeneca  
 Multi-parametric high-content screening to enable compound classification in drug discovery
10:00 (30 mins)
Yolanda Chong, Janssen Pharmaceutica  
 Novel in vitro and in silico models for the prediction of chemical toxicity
10:00 (30 mins)
Dominic Williams, Liverpool University  
 Antibody-Drug Conjugates (ADCs): The Magic Bullet Realized for Cancer Treatment?
10:00 (30 mins)
John Lambert, ImmunoGen  
 10:00
10:05 10:05
10:10 10:10
10:15 10:15
10:20 10:20
10:25 10:25
10:30 Coffee Break Coffee Break Coffee Break Coffee Break 10:30
10:35 10:35
10:40 10:40
10:45 10:45
10:50 10:50
10:55 10:55
11:00 Target Validation approaches in the CNS area
11:00 (30 mins)
Mark Carlton, Takeda Cambridge Ltd  
 Formats for High-throughput Biology in MIcrofluidic Droplets
11:00 (30 mins)
Florian Hollfelder, University of Cambridge  
 Developing High Fidelity Hepatotoxicity Models from Pluripotent Stem Cells
11:00 (30 mins)
David Hay, University of Edinburgh  
 Developing drugs in the diverse world of antibody therapeutics molecule
11:00 (30 mins)
David Matthews, MRC Technology  
 11:00
11:05 11:05
11:10 11:10
11:15 11:15
11:20 11:20
11:25 11:25
11:30 Poster Taster Presentations Poster Taster Presentations Poster Taster Presentations Poster Taster Presentations 11:30
11:35 11:35
11:40 11:40
11:45 11:45
11:50 11:50
11:55 11:55
12:00 Snapshot Presentations Stems cell bioprocessing: scaling up for drug discovery and the clinic
12:00 (30 mins)
Todd Upton, Corning  
 Snapshot Presentations Snapshot Presentations 12:00
12:05 12:05
12:10 12:10
12:15 12:15
12:20 12:20
12:25 12:25
12:30 Lunch Break Lunch Break Lunch Break Lunch Break 12:30
12:35 12:35
12:40 12:40
12:45 12:45
12:50 12:50
12:55 12:55
1:00 “The potential of microfluidics to improve in-vitro technologies for drug discovery”.
13:00 (45 mins)
Sabeth Verpoorte, University of Groningen  
“The potential of microfluidics to improve in-vitro technologies for drug discovery”.
13:00 (45 mins)
Sabeth Verpoorte, University of Groningen  
 1:00:
1:05: 1:05:
1:10: 1:10:
1:15: 1:15:
1:20: 1:20:
1:25: 1:25:
1:30: 1:30:
1:35: 1:35:
1:40: 1:40:
1:45: 1:45:
1:50: 1:50:
1:55: 1:55:
2:00 Practical applications of stem cell-derived cells within drug discovery
14:00 (60 mins)
Ruth McKernan, Pfizer  
 2:00:
2:05: 2:05:
2:10: 2:10:
2:15: 2:15:
2:20: 2:20:
2:25: 2:25:
2:30: 2:30:
2:35: 2:35:
2:40: 2:40:
2:45: 2:45:
2:50: 2:50:
2:55: 2:55:
3:00 The pharmacological playbook
15:00 (30 mins)
Jeremy Besnard, Dundee University  
 Automation for Human Pluripotent Stem Cells: Friend or Foe?
15:00 (30 mins)
Chris Denning, University of Nottingham  
 Use of in silico and in vitro models in a functional cardiovascular hazard identification strategy
15:00 (30 mins)
Jim Louttit, GSK  
 Oligonucleotides as novel therapeutics: where are we now?
15:00 (30 mins)
Mark Edbrooke, GSK  
 3:00:
3:05: 3:05:
3:10: 3:10:
3:15: 3:15:
3:20: 3:20:
3:25: 3:25:
3:30: Unravelling the therapeutic potential of Epigenetics through the application of Small Molecule Probe inhibitors
15:30 (30 mins)
Jason Witherington, GSK  
 Human stem cell derived cardiomyocytes in drug discovery and development
15:30 (30 mins)
Stefan Braam, Pluriomics  
 The value of DMPK assays in Drug Discovery and Development
15:30 (30 mins)
Dermot McGinnity, AstraZeneca Mölndal  
 Development of SASPject: A novel antibacterial platform technology
15:30 (30 mins)
Heather Fairhead, Phico Therapeutics  
 3:30:
3:35: 3:35:
3:40: 3:40:
3:45: 3:45:
3:50: 3:50:
3:55: 3:55:
4:00 Sleep EEG as a translational biomarker and target identification tool
16:00 (30 mins)
Keith Wafford, Eli Lilly  
 Novel Human patient models for drug development
16:00 (30 mins)
Rob Vries, Hurecht Institute  
 Modelling and Simulation: No Longer an Isolated Activity
16:00 (30 mins)
Amin Rostami, University of Manchester  
 ColoAd1: a self-replicating cancer vaccine
16:00 (30 mins)
Kerry Fisher, PsiOxus Therapeutics Ltd  
 4:00:
4:05: 4:05:
4:10: 4:10:
4:15: 4:15:
4:20: 4:20:
4:25: 4:25:
4:30: Poster Viewing Poster Viewing Poster Viewing Poster Viewing 4:30:
4:35: 4:35:
4:40: 4:40:
4:45: 4:45:
4:50: 4:50:
4:55: 4:55:
5:00 Drinks ReceptionDrinks Reception - Dragons Den Drinks Reception Drinks Reception Drinks Reception 5:00:
5:05: 5:05:
5:10: 5:10:
5:15: 5:15:
5:20: 5:20:
5:25: 5:25:
5:30: 5:30:
5:35: 5:35:
5:40: 5:40:
5:45: 5:45:
5:50: 5:50:
5:55: 5:55:
6:00 Drinks Reception 6:00: